<DOC>
	<DOCNO>NCT01958619</DOCNO>
	<brief_summary>A healthy volunteer study characterise exposure two study medication , follow administration OZ439 + TPGS granule piperaquine phosphate granule ( intended child ) piperaquine phosphate tablet ( intend adult ) . Ideally , confirm exposure demonstrate early bioavailability study .</brief_summary>
	<brief_title>Open Label Pharmacokinetic Study OZ439 Piperaquine Administration OZ439+TPGS Granules Oral Suspension Alone With Either Piperaquine Phosphate Tablets Granules Oral Solution Healthy Volunteers</brief_title>
	<detailed_description>A Phase 1 open label parallel group , four arm study conduct healthy male female subject age 18 55 year age . Subjects receive either treatment A , B , C D describe : - Treatment A : 1440 mg PQP tablets 800 mg OZ439 + TPGS granules oral suspension - Treatment B : 960 mg PQP tablets 800 mg OZ439 + TPGS granules oral suspension - Treatment C : 960 mg PQP granules oral solution 800 mg OZ439 + TPGS granules oral suspension - Treatment D : 800 mg OZ439 + TPGS granules oral suspension</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>healthy , male female , race age 1855 year screen body mass index 1830kg/m2 inclusive ; total body weight &gt; 50kg 100kg screening Females must negative pregnancy test screening , nonlactating nonchildbearing potential confirmed : natural ( spontaneous ) postmenopausal define amenorrheic 12 month without alternative medical cause screen FSH level &gt; 25IU/L post menopause irreversible surgical sterilisation bilateral oophorectomy bilateral salpingectomy tubal ligation ( without hysterectomy ) least six month ago Must agree use acceptable method contraception Males must use acceptable method contraception male subject 's partner could become pregnant time first administration treatment study medication 3 month follow administration last dose study medication One follow acceptable method contraception must use : Condom &amp; occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ) Surgical sterilisation ( vasectomy documentation azoospermia ) barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] use spermicidal foam/gel/film/cream/suppository ) Female partner use oral contraceptive ( combination oestrogen/progesterone pills ) , injectable progesterone subdermal implant barrier method ( ) Female partner use medically prescribe topicallyapplied transdermal contraceptive patch barrier method ( ) Female partner document tubal ligation ( sterilization ) . In addition , barrier method ( ) must use Female partner document placement intrauterine device system use barrier method ( ) True abstinence : line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Abstinent subject must agree use one abovementioned contraceptive method , sexual relationship start study 90 day last dose study drug Subjects donate egg sperm time administration study medication 3 month study medication Must capable understanding complying requirement protocol must sign informed consent form prior undergoing studyrelated procedure Male subject female partner ( ) ( ) pregnant lactate time administration study medication Has clinically significant disease condition disease might affect drug absorption , distribution excretion History allergic reaction artemisininbased compound , 4aminoquinolines piperaquine clinically relevant allergy drug food Any clinically significant abnormal laboratory , vital sign safety finding determine medical history , physical examination evaluation conduct screen admission History current evidence clinically relevant cardiovascular , pulmonary , hepatic , renal , gastrointestinal ( exclude appendectomy cholecystectomy ) , haematological , endocrinological , immunological , metabolic , neurological , oncological , psychiatric , urological disease , current infection History postantibiotic colitis Electrocardiogram abnormalities 12lead Electrocardiogram ( screen ) and/or 24hour Holter Electrocardiogram ( screen ) opinion Investigator clinically relevant interfere ECG analysis History clinically significant Electrocardiogram abnormality , follow abnormality screen admission : PR &gt; 200ms QRS complex &gt; 120ms QTcB QTcF &gt; 450ms shortened QTcB QTcF le 340ms male female family history long QT syndrome sudden death Any degree heart block ( first , second third degree atrioventricular block , incomplete , full intermittent bundle branch block ) Abnormal T wave morphology / prominent U wave Positive result serology test Hepatitis B Surface Antigen , anti Hepatitis core antibody , Hepatitis C antibody , HIV 1 2 antibody Confirmed positive result urine drug screen ( amphetamine , benzodiazepine , cocaine , cannabinoids , opiate , barbiturate , methadone ) alcohol breath test screen admission History clinical evidence alcohol abuse , recreational drug abuse within 2 year screen Mentally handicapped Participation drug trial within 90 day drug administration Use ANY prescription counter medication , within 3 week study medication administration , vitamins herbal supplement within 2 week administration study drug , unless prior approval grant . Intermittent use paracetamol dose 2g/day permit Use moderate/strong inhibitor and/or inducer CYP450 4 week drug administration ( least 5 halflives compound whichever long ) Veins unsuitable intravenous puncture cannulation either arm ( vein difficult locate , access puncture , vein tendency rupture puncture ) Transaminases , bilirubin , serum potassium outside normal range screen admission Haemoglobin &lt; low limit normal screen admission Donation &gt; 500mL blood 90 day prior drug administration Must nonsmoker least three month screen . `` Tobacco use '' include smoking use snuff chew tobacco , nicotine containing product . May use nonnicotine contain smoke cessation aid , e.g . varenicline , least three month screen Any consumption grapefruit , Seville oranges , wild grape , black mulberry , pomegranates fruit juice , marmalade raw fruit within 7 day prior dose study drug throughout study Any circumstance condition , may affect full participation trial compliance protocol Legal incapacity limit legal capacity screening Vegetarians , vegans dietary restriction conflict study standardise menu</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>open label</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>parallel group</keyword>
</DOC>